PG
LGND icon

PEAK6 Group’s Ligand Pharmaceuticals LGND Stock Holding History

PEAK6 Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,503
Closed -$1.29M – 4674
2018
Q1 		$1.29M Buy
12,503
+160
+1% +$15.8K 0.01% 1727
2017
Q4 		$1.05M Sell
12,343
-85,440
-87% -$7.41M ﹤0.01% 1872
2017
Q3 		$8.3M Buy
97,783
+1,282
+1% +$102K 0.04% 500
2017
Q2 		$7.31M Buy
96,501
+76,463
+382% +$5.35M 0.04% 511
2017
Q1 		$1.32M Sell
20,038
-31,098
-61% -$2.05M 0.01% 1464
2016
Q4 		$3.24M Buy
51,136
+2,565
+5% +$162K 0.02% 959
2016
Q3 		$3.09M Buy
48,571
+24,045
+98% +$1.77M 0.02% 986
2016
Q2 		$1.82M Buy
24,526
+22,121
+920% +$1.64M 0.01% 1307
2016
Q1 		$161K Buy
+2,405
New +$146K ﹤0.01% 3309
2015
Q3 		– Sell
-162,063
Closed -$10.2M – 5379
2015
Q2 		$10.2M Buy
162,063
+47,288
+41% +$2.58M 0.06% 429
2015
Q1 		$5.52M Buy
+114,775
New +$4.4M 0.04% 625

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PEAK6 Group's LGND Position: Q1 2018 in Review

PEAK6 Group sold out of Ligand Pharmaceuticals (LGND) in Q1 2018, closing a stake of 16,697 shares — an estimated $1.65M sold.

PEAK6 Group first reported a position in LGND in Q3 2015 and held it in 5 quarters. The position peaked at $1.57M in Q4 2016. 326 funds tracked by Wall St. Rank hold LGND as of Q1 2018.

  • PEAK6 Group reported no remaining Ligand Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • PEAK6 Group sold 16,697 Ligand Pharmaceuticals shares in Q1 2018, an estimated $1.65M.
  • PEAK6 Group first reported a position in Ligand Pharmaceuticals in Q3 2015 and held it in 5 quarters.
  • PEAK6 Group's Ligand Pharmaceuticals position peaked at $1.57M in Q4 2016.
  • 326 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2018.

Based on PEAK6 Group's 13F filing for Q1 2018, filed 15 May 2018.